XML 87 R41.htm IDEA: XBRL DOCUMENT v3.21.1
Collaboration and License Arrangement with Genentech - Additional Information (Detail)
 12 Months Ended
Dec. 31, 2020
USD ($)
Collaboration And License Arrangement [Line Items]  
Collaboration revenue $ 82,654,000
Contract asset $ 7,654,000
Genentech [Member] | Genentech Agreement [Member]  
Collaboration And License Arrangement [Line Items]  
Collaborative arrangement, purpose On December 11, 2020, the Company entered into the Genentech Agreement, which granted Genentech a license to develop and commercialize RLY-1971.
Collaborative arrangement, rights and obligations Unless Genentech elects to exercise its option to conduct the remainder of the ongoing Phase 1a Trial, the Company is responsible for the completion of this trial. Genentech is responsible for conducting all subsequent clinical development of RLY-1971. The Company is also responsible for the one-time transfer of the active pharmaceutical ingredient (“API”) and other materials related to RLY-1971 to Genentech
Non-refundable upfront payment $ 75,000,000
Milestone payment receivable 25,000,000
Maximum additional amount received upon milestone achievement 695,000,000
Collaboration agreement transaction price 85,867,000
Non-refundable milestone payment transfer amount 5,000,000
Non-refundable milestone payment for completion amount 5,000,000
Variable consideration related to reimbursements due for research and development services 867,000
Development based milestone payments under agreement 0
Regulatory based milestone payments under agreement 0
Genentech [Member] | Genentech Agreement [Member] | Transfer of License [Member]  
Collaboration And License Arrangement [Line Items]  
Collaboration revenue 82,654,000
Genentech [Member] | Genentech Agreement [Member] | Research and Development Services [Member]  
Collaboration And License Arrangement [Line Items]  
Collaboration revenue 0
Accounts receivable 75,000,000
Genentech [Member] | Genentech Agreement [Member] | Transfer of Active Pharmaceutical Ingredients [Member]  
Collaboration And License Arrangement [Line Items]  
Collaboration revenue 0
Contract asset 7,654,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member]  
Collaboration And License Arrangement [Line Items]  
Collaboration agreement transaction price 85,867,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member] | Transfer of License [Member]  
Collaboration And License Arrangement [Line Items]  
Remaining performance obligations 82,654,000,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member] | Research and Development Services [Member]  
Collaboration And License Arrangement [Line Items]  
Remaining performance obligations 2,896,000,000
Genentech [Member] | Genentech Agreement [Member] | Stand-alone Selling Prices (“SSP”) [Member] | Transfer of Active Pharmaceutical Ingredients [Member]  
Collaboration And License Arrangement [Line Items]  
Remaining performance obligations 317,000,000
Genentech [Member] | Genentech Agreement [Member] | Outside US [Member]  
Collaboration And License Arrangement [Line Items]  
Maximum additional amount received upon milestone achievement $ 410,000,000